RxDoctor Payments Data

Eduardo Flores, MD

Internal Medicine · Riverdale, MDNPI 1821081449

Payments from drug & device makers

$3,887in general payments, 2019–2025

Across 209 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$910
  • AstraZeneca$617
  • Lilly USA, LLC$419
  • Amgen$301
  • Sanofi-aventis U.S. LLC$284
  • Bayer$282
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,86899%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,887 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$230,928
Medicare patients
523
Services billed
5,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin110$180,534
MounjaroTirzepatide50$62,074
FarxigaDapagliflozin Propanediol35$53,248
RybelsusSemaglutide12$34,527
OzempicSemaglutide17$28,523
TrulicityDulaglutide24$24,779
EliquisApixaban25$20,370
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$12,483
Tresiba Flextouch U-100Insulin Degludec14$12,125
Breo ElliptaFluticasone/Vilanterol12$7,518
NorvascAmlodipine Besylate13$3,314
Rosuvastatin Calcium109$2,700
Albuterol Sulfate HfaAlbuterol Sulfate68$2,682
Atorvastatin Calcium210$1,557
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic18$1,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$176$180,534110 claims
Lilly USA, LLCMounjaro, Trulicity$419$86,85374 claims
AstraZenecaFarxiga, Breztri Aerosphere$617$65,73146 claims
Novo NordiskRybelsus, Ozempic$910$63,05029 claims
PfizerEliquis$237$20,37025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Riverdale

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →